Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA 510(k)

MARTIN-LEWIS AGAR W/REDUCED VANCOMYCIN C0226

K-Number: K871541 · 1987-04-29

ApplicantGibco Laboratories Life Technologies, Inc.
Decision Date1987-04-29
Product CodeJTY
Advisory CommitteeMI
DecisionSubstantially Equivalent

Device Summary

MARTIN-LEWIS AGAR W/REDUCED VANCOMYCIN C0226 is the device name listed in this FDA 510(k) record. The listed applicant is Gibco Laboratories Life Technologies, Inc.. It received FDA 510(k) clearance on 1987-04-29 under 510(k) number K871541. The device is classified under product code JTY. It was reviewed by the MI advisory panel. FDA Decision: Substantially Equivalent.

Frequently Asked Questions

What is the MARTIN-LEWIS AGAR W/REDUCED VANCOMYCIN C0226?

MARTIN-LEWIS AGAR W/REDUCED VANCOMYCIN C0226 is a medical device that received FDA 510(k) clearance on 1987-04-29. The listed applicant is Gibco Laboratories Life Technologies, Inc.. The 510(k) number is K871541.

When did MARTIN-LEWIS AGAR W/REDUCED VANCOMYCIN C0226 receive FDA 510(k) clearance?

MARTIN-LEWIS AGAR W/REDUCED VANCOMYCIN C0226 received FDA 510(k) clearance on 1987-04-29, under 510(k) number K871541.

Who is the listed applicant for MARTIN-LEWIS AGAR W/REDUCED VANCOMYCIN C0226?

The FDA 510(k) record lists Gibco Laboratories Life Technologies, Inc. as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for MARTIN-LEWIS AGAR W/REDUCED VANCOMYCIN C0226?

The FDA product code for MARTIN-LEWIS AGAR W/REDUCED VANCOMYCIN C0226 is JTY.

Related Clinical Trials

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITINGNCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITINGNCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDEDNCT07095751Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder CancerNOT_YET_RECRUITING

Other records listing Gibco Laboratories Life Technologies, Inc. as applicant

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

K871855SORBITOL MACCONKEY (SMAC) AGAR, DRI & PRE-FORMK870134MCBRIDE LISTERIA AGAR W/CYCLOHEXIMIDE, DRI & PREK864755PSEUDOMONAS CEPACIA SELECTIVE AGAR, DRI & PRE-FORMK864014LOMBARD DOWELL AGAR BASEK863821MUELLER HINTON AGAR W/4%NACL AND OXACILLINK863820DRI-FORM: GBNA LISTERIA MEDIUM NO. M22300

View all 67 devices →

Related Devices (Code: JTY)

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

K210511InTray GCBiomed Diagnostics IncorporatedK993033INTRAY GCBiomed Diagnostics, Inc.K954986GC BASE W/ 1% GCHIRemel, L.P.K950196CULTURE MEDIA, FOR ISOLATION OF PATHOGENIC NEISSERIABioclinical Systems, Inc.K933122MICROBIOLOGICAL CULTURE MEDIA,MARTIN LEWIS AGARBioclinical Systems, Inc.K933121MICROBIOLOGICAL CULTURE MEDIA,CHOCOLATE AGARBioclinical Systems, Inc.

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.

↑